Kenneth Gordon to Inflammatory Bowel Diseases
This is a "connection" page, showing publications Kenneth Gordon has written about Inflammatory Bowel Diseases.
Connection Strength
0.245
-
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 03 15; 190(4):477-485.
Score: 0.147
-
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan; 82(1):161-201.
Score: 0.027
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr; 80(4):1073-1113.
Score: 0.026
-
Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S48-S51.
Score: 0.024
-
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28; 375(4):345-56.
Score: 0.021